AR043418A1 - Formulaciones liquidas de las proteinas de union del factor necrosis del tumor - Google Patents

Formulaciones liquidas de las proteinas de union del factor necrosis del tumor

Info

Publication number
AR043418A1
AR043418A1 ARP040100618A ARP040100618A AR043418A1 AR 043418 A1 AR043418 A1 AR 043418A1 AR P040100618 A ARP040100618 A AR P040100618A AR P040100618 A ARP040100618 A AR P040100618A AR 043418 A1 AR043418 A1 AR 043418A1
Authority
AR
Argentina
Prior art keywords
tumor necrosis
liquid formulations
proteins tumor
factor
factor union
Prior art date
Application number
ARP040100618A
Other languages
English (en)
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of AR043418A1 publication Critical patent/AR043418A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una formulación estable, farmacéuticamente aceptable, acuosa de las proteínas de unión TNF, que comprende una proteína de unión TNF, un amortiguador y un agente de isotonicidad. Proceso para la preparación de una formulación farmacéutica líquida y forma de presentación de la misma.
ARP040100618A 2003-02-28 2004-02-27 Formulaciones liquidas de las proteinas de union del factor necrosis del tumor AR043418A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03100505 2003-02-28

Publications (1)

Publication Number Publication Date
AR043418A1 true AR043418A1 (es) 2005-07-27

Family

ID=32921619

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100618A AR043418A1 (es) 2003-02-28 2004-02-27 Formulaciones liquidas de las proteinas de union del factor necrosis del tumor

Country Status (22)

Country Link
US (3) US8937045B2 (es)
EP (1) EP1603596B1 (es)
JP (1) JP4980048B2 (es)
KR (1) KR20050105486A (es)
CN (1) CN100563712C (es)
AR (1) AR043418A1 (es)
AT (1) ATE394123T1 (es)
BR (1) BRPI0407649A (es)
CA (1) CA2515539A1 (es)
DE (1) DE602004013557D1 (es)
EA (1) EA009079B1 (es)
ES (1) ES2304602T3 (es)
HK (1) HK1085677A1 (es)
HR (1) HRP20050706A2 (es)
IL (1) IL170414A (es)
MX (1) MXPA05009135A (es)
NO (1) NO20054440L (es)
PL (1) PL213501B1 (es)
RS (1) RS51041B (es)
UA (1) UA82503C2 (es)
WO (1) WO2004075918A1 (es)
ZA (1) ZA200506504B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2707483A1 (en) * 2007-11-30 2009-06-11 Wolfgang Fraunhofer Protein formulations and methods of making same
WO2010129469A1 (en) * 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
PT2637690T (pt) 2010-11-11 2016-12-27 Abbvie Biotechnology Ltd Formulações líquidas de anticorpo anti-tnf-alfa de concentração elevada
CN103930124B (zh) 2011-07-01 2021-05-11 生物基因Ma公司 无精氨酸的tnfr：fc-融合多肽组合物及使用方法
PT2768525T (pt) * 2011-10-18 2019-07-17 Coherus Biosciences Inc Formulações etanercept estabilizadas com iões de magnésio
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
RS63948B1 (sr) 2011-10-31 2023-02-28 Hoffmann La Roche Formulacije anti-il13 antitela
IN2015KN00005A (es) 2012-07-09 2015-07-31 Coherus Biosciences Inc
ES2657377T3 (es) 2012-09-11 2018-03-05 Coherus Biosciences, Inc. Etanercept plegado correctamente con alta pureza y excelente rendimiento
KR102132050B1 (ko) 2012-10-26 2020-07-10 루핀 아틀란티스 홀딩스 에스에이 티엔에프알에프씨 융합 단백질의 안정한 약학 조성물
KR101692884B1 (ko) 2014-06-26 2017-01-04 마루이시세이야쿠가부시키가이샤 안정성을 개선한 로쿠로늄 제제
RU2724900C1 (ru) * 2019-10-24 2020-06-26 Маруиси Фармасьютикал Ко., Лтд. Препарат рокурония с улучшенной стабильностью

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
KR100232688B1 (ko) * 1992-09-15 1999-12-01 스코트 쥐. 홀퀴스트 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물
CA2139385C (en) * 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
DE69525181T2 (de) * 1995-07-14 2002-08-14 Applied Research Systems Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie
HRP970224A2 (en) * 1996-05-08 1998-04-30 Hoffmann La Roche TREATMENT OF ASTHMA WITH TNFR-Ig
PT942740E (pt) * 1996-12-06 2004-01-30 Amgen Inc Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
DE60322513D1 (de) * 2002-02-27 2008-09-11 Immunex Corp Stabilisierte TNFR-Fc Formulierung mit Arginin

Also Published As

Publication number Publication date
CA2515539A1 (en) 2004-09-10
AU2004216483A1 (en) 2004-09-10
ATE394123T1 (de) 2008-05-15
HRP20050706A2 (en) 2005-12-31
JP2006519210A (ja) 2006-08-24
MXPA05009135A (es) 2005-10-20
PL213501B1 (pl) 2013-03-29
WO2004075918A1 (en) 2004-09-10
US20070053906A1 (en) 2007-03-08
EP1603596A1 (en) 2005-12-14
EP1603596B1 (en) 2008-05-07
NO20054440L (no) 2005-09-26
US8937045B2 (en) 2015-01-20
EA200501230A1 (ru) 2006-04-28
ES2304602T3 (es) 2008-10-16
ZA200506504B (en) 2006-12-27
RS51041B (sr) 2010-10-31
KR20050105486A (ko) 2005-11-04
EA009079B1 (ru) 2007-10-26
BRPI0407649A (pt) 2006-02-21
JP4980048B2 (ja) 2012-07-18
US9512215B2 (en) 2016-12-06
CN100563712C (zh) 2009-12-02
PL378290A1 (pl) 2006-03-20
UA82503C2 (uk) 2008-04-25
DE602004013557D1 (de) 2008-06-19
HK1085677A1 (en) 2006-09-01
US20170020960A1 (en) 2017-01-26
CN1774266A (zh) 2006-05-17
IL170414A (en) 2009-11-18
US20150098950A1 (en) 2015-04-09
RS20050662A (en) 2007-11-15

Similar Documents

Publication Publication Date Title
NO20054440L (no) Flytende formuleringer av tumornekrosefaktorbindende proteiner
ECSP077261A (es) Composición de anticuerpo her2
PA8565101A1 (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo
UY27940A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a
PA8575701A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
CL2017000208A1 (es) Formulaciones de alta concentración de proteinas y anticuerpos (divisional de la solicitud n°142-2013)
BRPI0412241A (pt) formulação para medicamentos de proteìna sem adição de albumina de soro humano (hsa)
UY28184A1 (es) Formulaciones de inmunoglobulina y metodo de preparacion de la misma.
AR037629A1 (es) Formulaciones farmaceuticas que comprenden un derivado de platino
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
AR015598A1 (es) FORMULACIoN LIOFILIZADA QUE COMPRENDE PROTEíNA C ACTIVADA, SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO Y FORMA DE DOSIS UNITARIA QUE LA COMPRENDE.
HRP20020880B1 (en) New pharmaceutical composition
CR8220A (es) Composicion de fexofenadina y proceso para su preparacion
AR037592A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno
EE200400028A (et) Ravimpreparaat, selle valmistamise meetod ja selle kasutamine meditsiinis
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
NO20023551D0 (no) Ibuprofen-inneholdende aktivt middel-preparat
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
NO20054417L (no) Fremgangsmate for fremstilling av farmasoytiske preperater i form av fibratholdige tabletter og de derved fremstilte tabletter
SE0001916D0 (sv) Novel formulation
AR043370A1 (es) Composiciones farmaceuticas de administracion oral y metodos para evitar la interaccion alimento -droga
PT1178787E (pt) Composicoes farmacologicas para administracao por via oral de floroglucinol e suas preparacoes
NO20023249D0 (no) Nye substituerte pyrazolo(4,3-e)ediazepiner, farmasöytiske preparater inneholdende disse, anvendelse som medisinske produkterog fremgangsmåter for fremstilling derav
ITMI20021866A1 (it) Preparazione farmaceutica in forma colloidale utile nella cura delle affezioni cutanee.

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FA Abandonment or withdrawal
FA Abandonment or withdrawal